Enhancement of the CXCL12/CXCR4 Axis Due to Acquisition of Gemcitabine Resistance in Pancreatic Cancer: Effect of CXCR4 Antagonists

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2016 May 14

PMID 27175473

Citations 28

Authors

Mamoru Morimoto

Yoichi Matsuo

Shuji Koide

Ken Tsuboi

Tomoya Shamoto

Takafumi Sato

Kenta Saito

Hiroki Takahashi

Hiromitsu Takeyama

Affiliations

Soon will be listed here.

Abstract

Background: The CXCL12-CXCR4 signaling axis in malignant tumor biology has increased in importance, and these peptides are implicated in tumor growth, invasion and metastasis. The aim of our study was to examine the important role of the axis in pancreatic cancer (PaCa) cells' relationship with stromal cells in gemcitabine-resistant (GEM-R) tumors and to confirm the effectiveness of CXCR4 antagonists for the treatment of GEM-R PaCa cells.

Methods: We established two GEM-R PaCa cell lines using MIA PaCa-2 and AsPC-1 cells. The expression of CXCR4 mRNA in PaCa cells and the expression of CXCL12 mRNA in fibroblasts were examined by reverse transcription polymerase chain reaction (RT-PCR). The expression of CXCR4 protein in PaCa cells was examined by immunosorbent assay (ELISA) and immunocytochemistry. Using Matrigel invasion assays and animal studies, we then examined the effects of two CXCR4 antagonists, AMD11070 and KRH3955, on the invasiveness and tumorigenicity of GEM-R PaCa cells stimulated by CXCL12.

Results: We found that the expression of CXCR4 in GEM-R PaCa cells was significantly enhanced by GEM but not in normal GEM-sensitive (GEM-S) PaCa cells. In RT-PCR and ELISA assays, the production and secretion of CXCL12 from fibroblasts was significantly enhanced by co-culturing with GEM-R PaCa cells treated with GEM. In Matrigel invasion assays, the invasiveness of GEM-R PaCa cells treated with GEM was significantly activated by fibroblast-derived CXCL12 and was significantly inhibited by CXCR4 antagonists, AMD11070 and KRH3955. In vivo, the tumorigenicity of GEM-R PaCa cells was activated by GEM, and it was significantly inhibited by the addition with CXCR4 antagonists.

Conclusions: Our findings demonstrate that the CXCL12-CXCR4 signaling axis plays an important role in PaCa cells' resistance to GEM. CXCR4 expression was significantly enhanced by the exposure to GEM in GEM-R PaCa cells but not in GEM-S PaCa cells. Furthermore, CXCR4 antagonists can inhibit the growth and invasion of GEM-R PaCa cells. These agents may be useful as second-line chemotherapy for GEM-R PaCa in the future.

Citing Articles

Exploring the diversity of cancer-associated fibroblasts: insights into mechanisms of drug resistance.

Kazakova A, Lukina M, Anufrieva K, Bekbaeva I, Ivanova O, Shnaider P Front Cell Dev Biol. 2024; 12:1403122.

PMID: 38818409 PMC: 11137237. DOI: 10.3389/fcell.2024.1403122.

The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines.

Denda Y, Matsuo Y, Sugita S, Eguchi Y, Nonoyama K, Murase H Nutrients. 2024; 16(5).

PMID: 38474833 PMC: 10934733. DOI: 10.3390/nu16050705.

The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.

Lekan A, Weiner L Cancers (Basel). 2024; 16(3).

PMID: 38339310 PMC: 10854906. DOI: 10.3390/cancers16030559.

Deletion of the mRNA stability factor (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity.

McCarthy G, Di Niro R, Finan J, Jain A, Guo Y, Wyatt C NAR Cancer. 2023; 5(2):zcad016.

PMID: 37089813 PMC: 10113877. DOI: 10.1093/narcan/zcad016.

The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets.

Roberto M, Arrivi G, Di Civita M, Barchiesi G, Pilozzi E, Marchetti P Front Oncol. 2023; 13:1154581.

PMID: 37035150 PMC: 10076769. DOI: 10.3389/fonc.2023.1154581.

References

Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M . High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer. 2009; 100(9):1444-51. PMC: 2694427. DOI: 10.1038/sj.bjc.6605020. View

Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S . Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000; 6(9):3530-5. View

Banerjee S, Wang Z, Kong D, Sarkar F . 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009; 69(13):5592-600. PMC: 2743468. DOI: 10.1158/0008-5472.CAN-09-0838. View

Wong H, Lemoine N . Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009; 6(7):412-22. PMC: 2882232. DOI: 10.1038/nrgastro.2009.89. View

Skerlj R, Bridger G, Kaller A, McEachern E, Crawford J, Zhou Y . Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010; 53(8):3376-88. DOI: 10.1021/jm100073m. View

Hidalgo M . Pancreatic cancer. N Engl J Med. 2010; 362(17):1605-17. DOI: 10.1056/NEJMra0901557. View

Teicher B, Fricker S . CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010; 16(11):2927-31. DOI: 10.1158/1078-0432.CCR-09-2329. View

Singh S, Srivastava S, Bhardwaj A, Owen L, Singh A . CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 2010; 103(11):1671-9. PMC: 2994230. DOI: 10.1038/sj.bjc.6605968. View

Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N . Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011; 25(8):1314-23. PMC: 3135709. DOI: 10.1038/leu.2011.76. View

10.

Mosi R, Anastassova V, Cox J, Darkes M, Idzan S, Labrecque J . The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol. 2011; 83(4):472-9. DOI: 10.1016/j.bcp.2011.11.020. View

11.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

12.

Katsumoto K, Kume S . The role of CXCL12-CXCR4 signaling pathway in pancreatic development. Theranostics. 2013; 3(1):11-7. PMC: 3563076. DOI: 10.7150/thno.4806. View

13.

OBoyle G, Swidenbank I, Marshall H, Barker C, Armstrong J, White S . Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer. 2013; 108(8):1634-40. PMC: 3668477. DOI: 10.1038/bjc.2013.124. View

14.

Arora S, Bhardwaj A, Singh S, Srivastava S, McClellan S, Nirodi C . An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4. J Biol Chem. 2013; 288(29):21197-21207. PMC: 3774385. DOI: 10.1074/jbc.M113.484576. View

15.

Wu P, Lu Z, Cai B, Tian L, Zou C, Jiang K . Role of CXCL12/CXCR4 signaling axis in pancreatic cancer. Chin Med J (Engl). 2013; 126(17):3371-4. View

16.

Zhang H, Zhang L, Chen L, Li W, Li F, Chen Q . Stromal cell-derived factor-1 and its receptor CXCR4 are upregulated expression in degenerated intervertebral discs. Int J Med Sci. 2014; 11(3):240-5. PMC: 3917111. DOI: 10.7150/ijms.7489. View

17.

Guo F, Wang Y, Liu J, Mok S, Xue F, Zhang W . CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2015; 35(7):816-26. DOI: 10.1038/onc.2015.139. View

18.

Murphy P . Chemokines and the molecular basis of cancer metastasis. N Engl J Med. 2001; 345(11):833-5. DOI: 10.1056/NEJM200109133451113. View

19.

Homey B, Muller A, Zlotnik A . Chemokines: agents for the immunotherapy of cancer?. Nat Rev Immunol. 2002; 2(3):175-84. DOI: 10.1038/nri748. View

20.

Scozzafava A, Mastrolorenzo A, Supuran C . Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem. 2002; 17(2):69-76. DOI: 10.1080/14756360290024227. View